Tumor Cell Biology meeting 2015
Hotel ‘de Werelt’ Lunteren
Tuesday November 3rd, 2015

09.00 Registration and coffee

10.00 opening Frank v. Leeuwen

Session I: Tumor-immunology and -microenvironment
Chairs: Marjolein van Egmond and Anne-Marie Cleton-Jansen

10.15 Cisplatin enhances the response to immune checkpoint inhibitors in a mouse model for de novo invasive mammary tumorigenesis
K. Kersten, The Netherlands Cancer Institute, Amsterdam

10.30 T cell response facilitates cerebral metastasis of breast cancer
D.A. Mustafa, Erasmus MC, Rotterdam

10.45 The T-cell/CLL/macrophage triad shapes a supportive tumor microenvironment in CLL
M.H.A. van Attekum, AMC, Amsterdam

11.00 Pre-operative monoclonal antibody therapy prevents the development of liver metastasis, which are included by colorectal carcinoma resection
M. van Egmond, VUMC, Amsterdam

11.15 Coffee/Tea
Session II: Oncogenesis

Chairs: Ruud Delwel and Paul Coffer

11.45 Distribution of GNAQ and GNA11 mutation signatures in Uveal Melanoma points to a light dependent mutation mechanism
M.J. de Lange, LUMC, Leiden

12.00 Control of normal and cancer stem cell metabolism by PI3K/AKT/FOXO signalling
B.M.T. Burgering, UMCU, Utrecht

12.15 A tissue-specific transcriptional element for C/EBPA is required for HSC maintenance and neutrophil development
R. Avellino, Erasmus MC, Rotterdam

12.30 Tumor suppressor genes BTG1 and IKZF1 cooperate in leukemia development and glucorticoid therapy resistance
R. Marke, Radboudumc, Nijmegen

12.45 Protection against development of B cell lymphoma by tetraspanin CD37
C.M. de Winde, Radboudumc, Nijmegen

13.00 Lunch (14.00 hr: meeting project leaders)

14.30 Invited lecture
‘Niche business: Plasticity of cancer invasion, metastasis and therapy Response’
Peter Friedl, Radboudumc, Nijmegen + MD Anderson Cancer Center, Houston

15.15 BIOKE presentation
Edward Verwayen
Session III: Therapy(-resistance) and (pre-)clinical studies

Chairs: Jules Meijerink and Conny Jimenez

15.30  cSRC-mediated canonical Wnt activation in E-cadherin and HER2 positive and PR/ER negative mammary carcinoma cell lines
        J.A. Mol, Utrecht University, Utrecht

15.45  Targeted therapy of precancerous fields in the head and neck mucosa
        D.V. de Boer, VUMC, Amsterdam

16.00  CD44v/cMet signaling has an instrumental role in intestinal tumorigenesis
        S.P.J. Joosten, AMC, Amsterdam

16.15  Coffee/Tea

16.45  CRISPR/Cas9 based kinome screen identifies novel targets that determine sensitivity for Asparaginase therapy in Acute Lymphoblastic Leukemia
        M. Butler, Radboudumc, Nijmegen

17.00  Novel druggable targets in EGF receptor-mediated breast cancer antiestrogen resistance
        L. Wester, LUMC, Leiden

17.15  Neuroblastoma is a bi-phasic tumor with classic neuro-epithelial cells and chemo-resistant mesenchymal cells
        J. van Nes, AMC, Amsterdam
17.30 Identification of steroid resistance mechanisms in T-cell acute lymphoid leukemia by integrated genomic approaches
J.P.P. Meijerink, Erasmus MC, Rotterdam

17.45 Functional analysis of variants of uncertain significance in BRCA2
R. Mesman, LUMC, Leiden

18.00 Diner

20.00 Keynote Lecture

'Tumour blood vessels: New roles for old roads’

Kairbaan Hodivala-Dilke

Barts Cancer Institute, Queen Mary University of London

21.00 Disco (sponsored by Bioke) and drinks
Wednesday November 4th, 2015

Session IV: Gene regulation and genome organization
Chairs: Roland Kuiper and Geert Kops

09.00 The T-cell Acute Lymphoblastic Leukemia oncogene MEF2C collaborates with important transcriptional regulators for malignant transformation of early thymic progenitor cells
E. Vroegindeweij, Erasmus MC, Rotterdam

09.15 Kaiso represses gene transcription via a CpG-specific consensus site
M. Tenhagen, UMCU, Utrecht

09.30 Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in araganglioma/pheochromocytoma and smooth muscle tumors
A.S. Hoekstra, LUMC, Leiden

09.45 Radiosenstization through autophagy-inhibition; fact or artefact?
W.H.M. Hoevenaar, UMCU, Utrecht

10.00 Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function
J. de Lange, VUMC, Amsterdam

10.15 Deleterious germline BLM mutations and the risk for early-onset colorectal cancer
R.M. de Voer, Radboudumc, Nijmegen

10.30 Coffee/Tea
Session V: Invasion and metastasis

Chairs: Kees Jalink and Patrick Derksen

11.00 Autocrine leader cell induction and collective invasion through connexin-43 hemichannels and ADORA1
A.A. Khalil, University of Wuerzburg, Germany

11.15 Identification of molecular mechanisms responsible for neuroblastoma cell plasticity and therapy resistance
J. Middelbeek, Radboudumc, Nijmegen

11.30 MiR-520f reverses the EMT phenotype and inhibits metastasis
J.G.M. van Kampen, Radboudumc, Nijmegen

11.45 Growth factor receptor signaling maintains an epithelial phenotype in esophageal cancer
E.A. Ebbing, AMC, Amsterdam

12.00 KWF presentatie:
‘Introducing KWF funding principles 2016’
Wies van Roosmalen, KWF

12.15 Lunch

13.15 Invited Lecture
‘Genetic dissection of breast cancer development, therapy response and resistance in advanced mouse models’
Jos Jonkers, NKI
Session VI: DNA damage, repair and apoptosis

Chairs: Ruud Brakenhoff and Boudewijn Burgering

14.00   Expression of $\text{RAD51}^{A293T}$ leads to defective strand exchange activity in a dominant manner and is associated with a new FA subtype, “FA-R”
N. Ameziane, VUMC, Amsterdam

14.15   Correction of the Fanconi anemia complementation group F gene by CRISPR/Cas9 technology
H.J. van de Vrugt, The Netherlands Cancer Institute, Amsterdam

14.30   Coffee/Tea

15.00   FOXO maintains genomic stability by regulating histone acetylation around DSBs
S. van Doeselaar, UMCU, Utrecht

15.15   Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome
M. Drost, LUMC, Leiden

15.30   Targeted Apoptosis of Senescent Cells (TASC) against chemotoxicity and therapy resistance
P.L.J. de Keizer, Erasmus MC, Rotterdam

15.45   Best presentation awards and closure